Akari Therapeutics PLC (AKTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Akari Therapeutics PLC (AKTX) has a cash flow conversion efficiency ratio of -0.107x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.04 Million) by net assets ($28.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Akari Therapeutics PLC stock valuation for the company's overall valuation and market capitalisation.
Akari Therapeutics PLC - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Akari Therapeutics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Akari Therapeutics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Akari Therapeutics PLC ranked by their cash flow conversion efficiency. Explore how high is Akari Therapeutics PLC's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CYL Corporation Bhd
KLSE:7157
|
0.081x |
|
Yoshiharu Global Co.
NASDAQ:YOSH
|
-0.192x |
|
DIGIDRIVE DISTRIBUTORS LTD
NSE:DIGIDRIVE
|
N/A |
|
Chiangmai Rimdoi Public Company Limited
BK:CRD
|
0.179x |
|
Carbine Resources Ltd
AU:CRB
|
-0.045x |
|
Enduro Metals Corp
V:ENDR
|
-0.005x |
|
Pacific Nickel Mines Ltd
AU:PNM
|
-1.186x |
|
Garibaldi Resources Corp.
V:GGI
|
-0.013x |
Annual Cash Flow Conversion Efficiency for Akari Therapeutics PLC (2010–2025)
The table below shows the annual cash flow conversion efficiency of Akari Therapeutics PLC from 2010 to 2025. View today's stock price for Akari Therapeutics PLC for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $28.33 Million | $-10.57 Million | -0.373x | +33.93% |
| 2024-12-31 | $22.23 Million | $-12.55 Million | -0.565x | -100.79% |
| 2023-12-31 | $-229.00K | $-16.43 Million | 71.755x | +697.63% |
| 2022-12-31 | $1.79 Million | $-21.50 Million | -12.007x | -253.87% |
| 2021-12-31 | $5.55 Million | $-18.85 Million | -3.393x | -87.85% |
| 2020-12-31 | $9.38 Million | $-16.95 Million | -1.806x | +46.36% |
| 2019-12-31 | $3.84 Million | $-12.92 Million | -3.368x | -99.88% |
| 2018-12-31 | $13.38 Million | $-22.54 Million | -1.685x | -6.53% |
| 2017-12-31 | $19.98 Million | $-31.60 Million | -1.582x | -119.04% |
| 2016-12-31 | $34.10 Million | $-24.62 Million | -0.722x | -608.46% |
| 2015-12-31 | $48.72 Million | $-4.97 Million | -0.102x | +94.77% |
| 2014-12-31 | $4.85 Million | $-9.46 Million | -1.950x | -107.97% |
| 2013-12-31 | $5.81 Million | $-5.45 Million | -0.937x | -247.59% |
| 2012-12-31 | $-3.36 Million | $-2.13 Million | 0.635x | +56.57% |
| 2011-12-31 | $-2.48 Million | $-1.01 Million | 0.406x | +124.84% |
| 2010-12-31 | $-2.03 Million | $-366.00K | 0.180x | -- |
About Akari Therapeutics PLC
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat s… Read more